These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2097150)

  • 1. The modifications of T-lymphocyte cell subpopulations in patients with beta-interferon intracavitary treatment.
    Cherchi PL; Campiglio A; Rubattu A; Desole A; Andria G; Ambrosini A
    Eur J Gynaecol Oncol; 1990; 11(5):347-9. PubMed ID: 2097150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocavitary beta-interferon in neoplastic effusions.
    Cherchi PL; Campiglio A; Rubattu A; Desole A; Andria G; Ambrosini A
    Eur J Gynaecol Oncol; 1990; 11(6):477-9. PubMed ID: 2086232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients.
    Silver HK; Connors JM; Karim KA; Kong S; Spinelli JJ; de Jong G; McLean DM; Salinas FA
    J Biol Response Mod; 1983; 2(5):428-40. PubMed ID: 6644347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of natural killer activity and augmentation by OK-432 in patients with gynecological malignancies.
    Negishi Y; Miura M; Saito M; Sano Y; Akiya K; Fujiwara Y
    Gynecol Obstet Invest; 1986; 21(1):40-6. PubMed ID: 3485072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of recombinant interferon alpha-2 (Sch 30500) in advanced gynecological cancers].
    Kasamatsu T; Ohmi K; Takeuchi S; Takamizawa H; Matsuzawa M; Kawana T; Ueda K; Kubo H; Tsumuji Y; Kawashima Y
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1656-60. PubMed ID: 3896157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic modulation of metastatic breast and ovary carcinoma cells by intracavitary injection of IFN-alpha.
    Giacomini P; Mottolese M; Fraioli R; Benevolo M; Venturo I; Natali PG
    Br J Cancer; 1992 Aug; 66(2):342-4. PubMed ID: 1503908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Behavior of T-lymphocytes in patients with a gynecologic malignancy].
    Ressel M; Köhler G
    Zentralbl Gynakol; 1984; 106(17):1192-7. PubMed ID: 6333766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effects of human fibroblast interferon in advanced gynecological cancers].
    Kanazawa K; Honma S; Yuzawa H; Takeuchi S
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1276-83. PubMed ID: 6732254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Circulating T cells in patients with breast or genital cancers in the pre-therapeutic phase].
    Strache RR; Büttner HH; Kunze M; Röpcke G
    Zentralbl Gynakol; 1989; 111(12):816-23. PubMed ID: 2788342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours.
    Schöndorf T; Engel H; Lindemann C; Kolhagen H; von Rücker AA; Mallmann P
    Cancer Immunol Immunother; 1997 Apr; 44(2):88-96. PubMed ID: 9177470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical trial of interferon in gynecologic cancers].
    Sekiya S; Iwasawa H; Ishige H; Takamizawa H
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jul; 37(7):1241-3. PubMed ID: 4040950
    [No Abstract]   [Full Text] [Related]  

  • 13. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
    Mallmann P; Krebs D
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.
    Kalli KR; Block MS; Kasi PM; Erskine CL; Hobday TJ; Dietz A; Padley D; Gustafson MP; Shreeder B; Puglisi-Knutson D; Visscher DW; Mangskau TK; Wilson G; Knutson KL
    Clin Cancer Res; 2018 Jul; 24(13):3014-3025. PubMed ID: 29545464
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
    Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
    Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.
    Kosmas C; Epenetos AA; Courtenay-Luck NS
    Br J Cancer; 1991 Sep; 64(3):494-500. PubMed ID: 1911190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Morphological and immunologic changes following intratumoral administration of alpha interferon in patients with breast cancer].
    Polevaia EB; Ermilova VD; Kupin VI
    Vopr Onkol; 1986; 32(12):19-23. PubMed ID: 3492075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunologic studies in patients with ovarian carcinoma during radio-chemotherapy. I. Studies of lymphocyte subpopulations].
    Vahrson H; Li L; Pralle H
    Strahlenther Onkol; 1991 Nov; 167(11):643-50. PubMed ID: 1962278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas.
    Dutsch-Wicherek M; Wicherek L
    Am J Reprod Immunol; 2008 Mar; 59(3):266-75. PubMed ID: 18275520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes.
    Soda H; Koda K; Yasutomi J; Oda K; Takiguchi N; Saito N; Nakajima N
    J Surg Oncol; 1999 Dec; 72(4):211-7. PubMed ID: 10589036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.